Suppr超能文献

与单独使用肌钙蛋白I相比,联合使用不同的心肌缺血生化标志物并不能改善胸痛患者的风险分层。

Combining different biochemical markers of myocardial ischemia does not improve risk stratification in chest pain patients compared to troponin I alone.

作者信息

Eggers Kai M, Oldgren Jonas, Nordenskjöld Anna, Lindahl Bertil

机构信息

Department of Cardiology, University Hospital, Uppsala, Sweden.

出版信息

Coron Artery Dis. 2005 Aug;16(5):315-9. doi: 10.1097/00019501-200508000-00009.

Abstract

OBJECTIVE

Early evaluation of patients with chest pain is important not only for the detection of acute myocardial infarction (AMI) but also for identification of patients at high risk for future cardiac events. A multimarker strategy applying results of early measurements of different biochemical markers of cardiac necrosis in combination may improve risk prediction in chest pain patients.

METHODS

Rapid measurements of troponin I (TnI), creatine kinase MB and myoglobin were performed in 191 consecutive patients with chest pain and a non-diagnostic electrocardiogram for AMI. The prognostic value of these markers and different multimarker strategies was evaluated and compared.

RESULTS

Ten (5.2%) patients died during follow-up, which for eight (4.2%) patients was due to cardiac causes. Myocardial reinfarctions occurred in 17 (6.8%) patients. TnI was most predictive for cardiac mortality (TnI>or=0.1 microg/l, 10.7% event rate compared with TnI<0.1 microg/l, 0%, P<0.001) and myocardial reinfarction (14.9% compared with 1.7%, P<0.001). The other markers and multimarker strategies had a lower capacity for predicting adverse events apart from myoglobin and the combination of TnI or myoglobin regarding the endpoint of total mortality.

CONCLUSION

The combinations of different markers were prognostically non-superior compared to TnI, which thus, should be preferred as a biochemical marker for risk stratification in patients with chest pain.

摘要

目的

对胸痛患者进行早期评估不仅对急性心肌梗死(AMI)的检测很重要,而且对于识别未来发生心脏事件的高危患者也很重要。采用心脏坏死不同生化标志物早期测量结果的多标志物策略可能会改善胸痛患者的风险预测。

方法

对191例连续的胸痛患者且心电图对AMI诊断不明确的患者进行肌钙蛋白I(TnI)、肌酸激酶同工酶MB和肌红蛋白的快速检测。评估并比较这些标志物及不同多标志物策略的预后价值。

结果

10例(5.2%)患者在随访期间死亡,其中8例(4.2%)患者死于心脏原因。17例(6.8%)患者发生心肌再梗死。TnI对心脏死亡率(TnI≥0.1μg/L,事件发生率为10.7%,而TnI<0.1μg/L时为0%,P<0.001)和心肌再梗死(分别为14.9%和1.7%,P<0.001)的预测性最强。除肌红蛋白以及就总死亡率终点而言TnI或肌红蛋白的组合外,其他标志物和多标志物策略预测不良事件的能力较低。

结论

与TnI相比,不同标志物的组合在预后方面并无优势,因此,TnI应作为胸痛患者风险分层的生化标志物首选。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验